Long-term Data: INPULSIS®-ON

Slides:

Advertisements

Similar presentations

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Advertisements

Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.

Can we prevent stent restenosis after coronary stent implantation

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

FREEDOMS II TRIAL.

Rituximab for the Treatment of Rheumatoid Arthritis

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.

Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Acute Rhinitis. Results Yakoot, M., Amel, S. (2011). Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management.

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

INPULSIS® trial design and baseline characteristics

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

4S: Scandinavian Simvastatin Survival Study

OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) second interim analysis in.

OFEV ® (nintedanib) efficacy INPULSIS ® trial results for acute IPF exacerbations Last updated These slides are provided by Boehringer Ingelheim.

Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Safety and tolerability

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Attal M et al. Proc ASH 2010;Abstract 310.

Gajria D et al. Proc SABCS 2010;Abstract P

OFEV® (nintedanib) efficacy

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

IPF treatment with nintedanib

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Early Clinical Experiences with Nintedanib in 3 Tertiary Interstitial Lung Disease Centres

Filming: 15th of Febuary 2016, London, UK

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.

Phase 2 Treatment Naïve Injection Drug Use

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Barrios C et al. SABCS 2009;Abstract 46.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Nintedanib Dose Modifications

Krop I et al. SABCS 2009;Abstract 5090.

Filming: 15th of Febuary 2016, London, UK

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Baselga J et al. SABCS 2009;Abstract 45.

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

Phase 2b Treatment Naïve and Treatment Experienced

This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.

WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Screening, Lipid Stabilization, and Placebo Run-in

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.

Switch to RAL-containing regimen

The FAIR-HF Trial Reference

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Patient disposition, weeks 24–128.

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

New Models of Care in Idiopathic Pulmonary Fibrosis

This comparative clinical trial of IV epoetin alfa-epbx versus epoetin alfa was a randomized, active-controlled, parallel-group, double-blind study including.

PHOENIX I: PASI 75 Response After 12 Weeks

Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac.

Presentation transcript:

Long-term Data: INPULSIS®-ON Filming: 15th of Febuary 2016, London, UK Prof. Vincent Cottin Prof. Luca Richeldi

INPULSIS® and INPULSIS®-ON: Study design1,2 Patients who completed the 52-week treatment period and follow-up visit 4 weeks later in an INPULSIS® trial were eligible to enter INPULSIS®-ON. Dose reduction to 100 mg bid and treatment interruption were allowed to manage adverse events; dose re-escalation to 150 mg bid was permitted. INPULSIS® INPULSIS®-ON Patients randomized 3:2 To receive either nintedanib or placebo Double-blind, placebo-controlled Open-label extension trial Nintedanib 150 mg bid (n= 638) Continuing nintedanib (n=430) R Placebo (n=423) Initiating nintedanib (n=304) 52 Weeks (trial period) No treatment* *Per protocol, the off-treatment period between INPULSIS® and INPULSIS®-ON could be between 4 and 12 weeks. 1. Crestani B, et al. Abstract presented at ERS 2015. 2. Richeldi L, et al. NEJM 2014;370:2071–2082. references

Exposure times in INPULSIS® and INPULSIS®-ON Mean (SD; min–max) total duration of exposure for patients treated with nintedanib in both INPULSIS® and INPULSIS®-ON was 29.2 (6.6; 11.9–40.6) months.1 Exposure times (Interim analysis: November 2014)1 INPULSIS® INPULSIS®-ON Nintedanib (n=638) Placebo (n=423) Continuing nintedanib (n=430) Initiating nintedanib (n=304) Exposure, months Mean (SD) 10.3 (3.4) 10.8 (2.8) 17.2 (6.6) 16.0 (7.3) Minimum, maximum 0.0, 12.7 0.0, 13.1 0.1, 28.8 0.0, 28.8 1. Crestani B, et al. Abstract presented at ERS 2015. references

Pooled INPULSIS® analysis at 52 weeks1 An interim analysis of the INPULSIS®-ON trial confirmed the long-term efficacy of nintedanib in patients with IPF1,2 Change from baseline in FVC at week 52 in INPULSIS® and at week 48 in INPULSIS®-ON1,2 Pooled INPULSIS® analysis at 52 weeks1 INPULSIS®-ON at 48 weeks2 Nintedanib (n=519) Placebo (n=345) Continuing nintedanib (n=352) Initiating nintedanib (n=233) Mean (SEM) observed change from baseline in FVC (mL) 1. Richeldi L, et al. NEJM 2014;370:2071–2082. 2. Crestani B, et al. Abstract presented at ERS 2015. references

Safety and tolerability profile of nintedanib confirmed beyond 2 years1,2 Adverse Events (Interim analysis: November 2014)1 N (%) INPULSIS® INPULSIS®-ON Nintedanib (n=638) Placebo (n=423) Continuing nintedanib (n=430) Initiating nintedanib (n=304) Exposure, months, mean (SD) 10.3 (3.4) 10.8 (2.8) 17.2 (6.6) 16.0 (7.3) Adverse events 609 (95.5) 379 (89.6) 399 (92.8) 294 (96.7) Severe adverse events 174 (27.3) 99 (23.4) 130 (30.2) 104 (34.2) Adverse events leading to drug discontinuation 123 (19.3) 55 (13.0) 86 (20.0) 87 (28.6) Serious adverse events 194 (30.4) 127 (30.0) 180 (41.9) 120 (39.5) Fatal adverse events 37 (5.8) 31 (7.3) 45 (10.5) 30 (9.9) There were no new safety concerns identified after 2 years.1,2 *A severe adverse event was related to intensity and was defined as an event that was incapacitating or that caused an inability to work or to perform usual activities. **A serious adverse event was defined as any adverse event that resulted in death, was immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged hospitalization, was related to a congenital anomaly or birth defect, or was deemed serious for any other reason. 1. Crestani B, et al. Abstract presented at ERS 2015. 2. Crestani B, et al. AJRCCM 191;2015:A1020.

Safety and tolerability profile of nintedanib confirmed beyond 2 years1,2 Special Adverse Events: Cardiac and Bleeding Adverse Events (Interim analysis: November 2014)1 N (%) INPULSIS® INPULSIS®-ON Nintedanib (n=638) Placebo (n=423) Continuing nintedanib (n=430) Initiating nintedanib (n=304) Exposure, months, mean (SD) 10.3 (3.4) 10.8 (2.8) 17.2 (6.6) 16.0 (7.3) Cardiac disorders* 64 (10.0) 45 (10.6) 57 (13.3) 32 (10.5) Serious cardiac disorders* 32 (5.0) 23 (5.4) 23 (5.3) 15 (4.9) Ischaemic heart disease† 27 (4.2) 17 (4.0) 20 (4.7) 9 (3.0) Myocardial infarction 7 (1.1) 2 (0.5) 3 (0.7) 0 (0.0) Acute myocardial infarction 3 (0.5) 1 (0.2) Bleeding‡ 66 (10.3) 33 (7.8) 45 (10.5) 28 (9.2) Serious bleeding‡ 8 (1.3) 6 (1.4) 4 (0.9) *System organ class. †Based on broad scope definition of SMQs. ‡Bleeding is based on standardised MedDRA query “haemorrhage terms (excluding laboratory terms)”. 1. Crestani B, et al. Abstract presented at ERS 2015. references

Conclusions An interim analysis of the INPULSIS®-ON trial confirmed the long-term efficacy and safety profile of nintedanib in patients with IPF: The decline in FVC in patients continuing or initiating nintedanib in INPULSIS®- ON was similar to the decline in FVC with nintedanib in INPULSIS®. This suggests that the treatment effect of nintedanib on slowing disease progression persists for 2 years. Long-term nintedanib treatment (up to 40 months) had a manageable safety and tolerability profile, with no new safety signals identified. 1. Crestani B, et al. Abstract presented at ERS 2015.